Protagonist Therapeutics (PTGX) Cash from Investing Activities (2015 - 2026)

Protagonist Therapeutics has disclosed Cash from Investing Activities across 12 years of filings, most recently posting $90.9 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $90.9 million, up 196.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $136.0 million (up 133.99% YoY), and the FY2025 annual result was -$49.3 million, up 83.53% from the prior year.
• Cash from Investing Activities came in at $90.9 million for Q1 2026 at Protagonist Therapeutics, up from $48.8 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $90.9 million in Q1 2026 to a low of -$208.7 million in Q3 2024.
• The 5-year median for Cash from Investing Activities is $3.9 million (2022), against an average of -$12.1 million.
• Across the five-year window, Cash from Investing Activities plunged 1657.48% in 2023 and jumped 659.48% in 2025, its largest moves.
• Protagonist Therapeutics' Cash from Investing Activities stood at $3.9 million in 2022, then slumped by 1657.48% to -$61.3 million in 2023, then jumped by 85.76% to -$8.7 million in 2024, then surged by 659.48% to $48.8 million in 2025, then jumped by 86.2% to $90.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $90.9 million (Q1 2026), $48.8 million (Q4 2025), and -$58.6 million (Q3 2025), per Business Quant data.